Researchers at MIT and Massachusetts General Hospital have unveiled an artificial intelligence system that can detect early signs of cancer up to five years before traditional diagnostic methods.\n\nThe system, called OncoSight, analyzes routine blood tests to identify subtle patterns of biomarkers that human doctors cannot perceive. In clinical trials involving 50,000 patients, it achieved a 95% accuracy rate in predicting cancer development.\n\n"This could fundamentally change how we fight cancer," said Dr. James Park, the lead researcher. "Early detection is the single most important factor in survival rates."\n\nThe technology is expected to be available in hospitals within two years and could save an estimated 1 million lives annually worldwide.